- F&P Healthcare revised its full-year net income forecast to NZ$320 million to NZ$370 million, up from the previous range of NZ$310 million to NZ$360 million.
- Analysts’ estimate for net income stands at NZ$342.1 million.
- The company still expects its operating revenue for the year to be between NZ$1.9 billion to NZ$2 billion, with analysts estimating NZ$1.97 billion.
- First-half (1H) revenue is predicted to be between NZ$940 million to NZ$950 million.
- First-half (1H) net income is forecasted at NZ$150 million to NZ$160 million.
- The year-to-date performance has been strong across all product lines.
- High hospital admissions have persisted due to seasonal hospitalizations.
- The company notes progress with gross margin improvement initiatives.
- Analyst ratings include 2 buys, 8 holds, and 5 sells.
A look at Fisher & Paykel Healthcare Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts evaluating Fisher & Paykel Healthcare Corp‘s future potential have awarded the company a mixed outlook based on Smartkarma Smart Scores. The company received a moderate score of 2 in both the Value and Dividend categories, indicating a fair valuation and dividend potential. However, Fisher & Paykel Healthcare Corp scored higher in Growth with a 3, suggesting promising growth prospects. Furthermore, the company demonstrated strong resilience with a score of 4 and solid momentum with a top score of 5, indicating a robust ability to weather challenges and maintain positive performance momentum.
Fisher & Paykel Healthcare Corporation Limited, known for designing, manufacturing, and marketing respiratory care and sleep apnea treatment products, also offers patient warming and neonatal care solutions such as warming products and infant resuscitators. With a diverse product portfolio catering to healthcare needs, the company’s overall outlook, as indicated by Smartkarma Smart Scores, reflects a combination of steady value, growth potential, resilience, and positive momentum in the market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
